SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Vidpok13/10/2016 12:12:30 PM
   of 4474
 
The disparity between the IBB and Ariad continues to widen. The IBB is off the low by 6 percent while Ariad exceeds the low by 46 percent. The only thing to explain this widening differential is to assume that while investors continue to avoid the "risky" biotech sector in general, apparently investors understand the compelling potential for growth for Ariad under the new regime. One can extrapolate where Ariad will be once the biotech sector gains some traction which hasn't really been in evidence yet. It isn't a stretch to see Ariad back in double digits when the sector returns to its former state of grace among investors which it undoubtedly will at some point (within the next few months I would think). Then the talk of a buyout in the 20s will inevitably (correctly) return.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News